Every 424B that Immix Biopharma, Inc. (IMMX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IMMX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMMX filings page.
Immix Biopharma, Inc. is offering 11,363,637 shares of common stock at $11.00 per share, for a stated aggregate public offering price of $125,000,007. Estimated net proceeds are approximately $117.1 million after underwriting discounts and estimated offering expenses; the company intends to use them for NXC-201 clinical development, working capital and general corporate purposes. The prospectus estimates immediate dilution of $6.83 per share for offering purchasers, with pro forma, as-adjusted net tangible book value of approximately $4.17 per share.
Updated Phase 2 NEXICART-2 data report complete responses in 40 of 45 relapsed/refractory AL amyloidosis patients (89%), as assessed by an independent review committee. All 25 new patients were either in complete response or already MRD-negative. Four pending patients who were already MRD-negative could potentially increase the future complete response rate to up to 98% (44/45). No relapses had been observed to date among patients who reached complete response or MRD-negativity.
Immix Biopharma is offering 16,778,524 shares of common stock at $8.94 per share. The prospectus supplement states net proceeds are estimated at approximately $140.65 million to fund NXC-201 clinical development, working capital and general corporate purposes. Shares outstanding immediately after the offering are shown as 69,790,616.
The filing notes clinical progress for CAR-T candidate NXC-201, including a reported 95% CR rate (19/20) among an early cohort in NEXICART-2 and regulatory designations such as RMAT, ODD and Breakthrough Therapy. Management retains broad discretion over use of proceeds and lock-up and stabilization arrangements are described.
Immix Biopharma, Inc. proposes to offer up to $100,000,000 of Common Stock in an at-the-market offering pursuant to an ATM Agreement with Citizens JMP Securities, LLC, as amended on March 25, 2026.
The ATM permits sales from time to time on the Nasdaq Capital Market or through other permitted methods. Citizens will receive a 3.0% commission on gross sales and will be deemed an underwriter for Securities Act purposes. Proceeds to the company will vary based on actual shares sold and market prices.
Shares outstanding were 52,964,549 as of March 20, 2026, and the prospectus illustration shows up to 63,941,497 shares outstanding after the offering assuming sale of 10,976,948 shares at $9.11 per share.